Abstract
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for the treatment of newly diagnosed as well as relapsed refractory multiple myeloma. Preclinical data supported dararumumab ability in depleting autoantibodies producing-plasma cells, B-cells as well as NK cells. Those reports showed promising results on the use of daratumumab in autoimmune disorders refractory to multiple lines of therapies, which encouraged the use of daratumumab in various autoimmune conditions that are refractory to standard therapies. The aim of this review is to summarize the literature reporting experience using anti-CD38 antibodies in hematological autoimmune diseases, focusing on the most common autoimmune hematological diseases including autoimmune hemolytic anemia, immune thrombocytopenia, post-transplant cytopenia and we will include pure red blood cell aplasia.
Recommended Citation
Yang, Erin Huilin; Muhsen, Ibrahim N.; Samarkandi, Hadeel; Fakih, Riad El; Aljurf, Mahmoud; and Hanbali, Amr
(2023)
"Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases.,"
Hematology/Oncology and Stem Cell Therapy: Vol. 17
:
Iss.
1
, Article 6.
Available at: https://doi.org/10.56875/2589-0646.1108
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
